Breakthrough status is confidential by law

A product code with a known competitor pipeline eventually raises the question: is that device Breakthrough? For most FDA pathways, the record answers a question like that directly. For Breakthrough Device designation, the record cannot answer it at all before authorization — not because openFDA left a field out, but because federal law tells FDA not to say.

What the statute actually withholds

21 U.S.C. 360e-3, added by the 21st Century Cures Act and amended twice since, is the authority behind the Breakthrough Devices Program. Requests for designation travel as confidential Q-Submissions, and before a device reaches marketing authorization, FDA generally may not disclose that a sponsor even asked for designation, let alone whether it was granted or denied, unless the sponsor chooses to say so itself. That is a statutory default, not a policy FDA could relax by publishing a list. A pending 510(k), De Novo request, or PMA under review carries no public field for this, because the law does not let one exist yet.

The one moment it becomes public

The confidentiality has an end point, and FDA has committed to it in guidance: once a designated device reaches marketing authorization for the indication the designation covered, FDA discloses the designation and adds the device to its own public list. Before that moment: nothing. After it: the record updates in one retroactive step, with no earlier signal to have tracked. A device that clears without ever appearing on that list looks, from any public record, exactly like one that was never designated — and a device that clears while carrying an undisclosed designation looks, until the list updates, identical to the same thing.

A designation FDA is not yet permitted to disclose and a designation that was never requested produce the identical public record: nothing. Absence is not evidence either way, and no field distinguishes the two cases from the outside.

The practice

What fills the gap in practice is not FDA data; it is the sponsor’s own disclosure — a press release, an investor deck, a conference slide — made voluntarily, on the sponsor’s own timeline, because the statute lets the sponsor speak even when FDA cannot. Treat that kind of announcement as the only reliable pre-authorization signal, and treat its absence as uninformative rather than as a finding: a competitor that has said nothing may hold designation and simply not have chosen to announce it yet. Watch FDA’s public list for the retroactive update once a designated device authorizes, and do not expect a structured feed, FDA Radar’s included, to flag designation status any earlier — no public source carries the fact yet to ingest. What a competitor’s designation status implies for your own program is a judgment for a regulatory professional reading the filing; this, like the rest of Signals, is regulatory intelligence and method, never regulatory advice about what your own program’s disclosure should be.

FDA Radar ingests 510(k), PMA, and classification records daily, exactly as published; see what we monitor and how often for the rest of the pipeline. None of those records carry a breakthrough field before authorization, because none can — the statute governs what FDA publishes, not what any downstream product chooses to show.